NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone

NeOnc Technologies reported that a critically ill three-year-old with an aggressive brain tumor is breathing independently and beginning to move his legs after receiving investigational intranasal NEO100 through its Compassionate Care program in Abu Dhabi. The company itself cautions that a single compassionate-use case cannot establish the drug caused the improvement, and the treatment was administered outside its pediatric clinical trial.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.